Wainua is an RNA-targeted medication designed to treat hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic condition causing organ damage. Administered via injection, it reduces production of abnormal TTR protein, slowing disease progression. Adults with confirmed hATTR, especially those experiencing neuropathy or cardiomyopathy, benefit from this therapy to preserve function and quality of life.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends